Collegium Pharmaceutical Inc
COLL36.160USD
+0.620+1.74%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
1.14BValor de mercado
31.45P/L TTM
Mais detalhes de Collegium Pharmaceutical Inc Empresa
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.
Informações da empresa
Código da empresaCOLL
Nome da EmpresaCollegium Pharmaceutical Inc
Data de listagemMay 07, 2015
CEOMr. Vikram Karnani
Número de funcionários357
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 07
Endereço100 Technology Center Dr
CidadeSTOUGHTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02072-4710
Telefone17817133699
Sitehttps://www.collegiumpharma.com/
Código da empresaCOLL
Data de listagemMay 07, 2015
CEOMr. Vikram Karnani
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Vikram Karnani
Mr. Vikram Karnani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.97K
--
Mr. David Dieter
Mr. David Dieter
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
68.45K
--
Mr. Gino Santini
Mr. Gino Santini
Independent Chairman of the Board
Independent Chairman of the Board
44.83K
+27.23%
Ms. Colleen Tupper
Ms. Colleen Tupper
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
42.18K
-37.97%
Dr. Rita J. Balice-Gordon, Ph.D.
Dr. Rita J. Balice-Gordon, Ph.D.
Independent Director
Independent Director
33.77K
+40.84%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
22.52K
+76.94%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Director
Independent Director
19.58K
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Dr. John A. Fallon, M.D.
Dr. John A. Fallon, M.D.
Independent Director
Independent Director
--
--
Ms. Jane Gonnerman
Ms. Jane Gonnerman
Executive Vice President - Strategy and Corporate Development
Executive Vice President - Strategy and Corporate Development
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Vikram Karnani
Mr. Vikram Karnani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.97K
--
Mr. David Dieter
Mr. David Dieter
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
68.45K
--
Mr. Gino Santini
Mr. Gino Santini
Independent Chairman of the Board
Independent Chairman of the Board
44.83K
+27.23%
Ms. Colleen Tupper
Ms. Colleen Tupper
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
42.18K
-37.97%
Dr. Rita J. Balice-Gordon, Ph.D.
Dr. Rita J. Balice-Gordon, Ph.D.
Independent Director
Independent Director
33.77K
+40.84%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
22.52K
+76.94%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Nucynta IR
75.06M
42.23%
Xtampza ER
51.66M
29.06%
Jomay PM
28.54M
16.06%
Belbuca
27.42M
15.42%
Nucynta ER
19.69M
11.07%
Symproic
2.81M
1.58%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Nucynta IR
75.06M
42.23%
Xtampza ER
51.66M
29.06%
Jomay PM
28.54M
16.06%
Belbuca
27.42M
15.42%
Nucynta ER
19.69M
11.07%
Symproic
2.81M
1.58%
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
14.93%
Rubric Capital Management LP
9.94%
Eventide Asset Management, LLC
8.38%
The Vanguard Group, Inc.
7.08%
Renaissance Technologies LLC
4.83%
Outro
54.83%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
14.93%
Rubric Capital Management LP
9.94%
Eventide Asset Management, LLC
8.38%
The Vanguard Group, Inc.
7.08%
Renaissance Technologies LLC
4.83%
Outro
54.83%
Tipos de investidores
Investidores
Proporção
Investment Advisor
57.56%
Investment Advisor/Hedge Fund
34.73%
Hedge Fund
18.95%
Research Firm
3.22%
Individual Investor
1.80%
Pension Fund
1.36%
Bank and Trust
0.45%
Sovereign Wealth Fund
0.42%
Insurance Company
0.04%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
512
38.21M
121.28%
-5.18M
2025Q1
528
38.32M
119.23%
-5.70M
2024Q4
520
38.61M
122.59%
-6.60M
2024Q3
498
39.90M
123.83%
-6.67M
2024Q2
486
41.00M
125.33%
-4.08M
2024Q1
464
41.14M
125.78%
-3.32M
2023Q4
434
40.31M
123.54%
-3.32M
2023Q3
425
39.87M
114.82%
-4.18M
2023Q2
428
40.45M
116.96%
-4.39M
2023Q1
425
40.62M
117.50%
-1.29M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
4.84M
15.05%
-111.68K
-2.26%
Mar 31, 2025
Rubric Capital Management LP
3.00M
9.33%
+650.00K
+27.66%
Mar 31, 2025
Eventide Asset Management, LLC
2.64M
8.21%
+845.00
+0.03%
Mar 31, 2025
The Vanguard Group, Inc.
2.24M
6.97%
-36.10K
-1.59%
Mar 31, 2025
Renaissance Technologies LLC
1.62M
5.03%
-45.50K
-2.74%
Mar 31, 2025
Principal Global Investors (Equity)
1.57M
4.89%
-71.69K
-4.36%
Mar 31, 2025
Fuller & Thaler Asset Management Inc.
1.37M
4.27%
+19.57K
+1.45%
Mar 31, 2025
Emerald Advisers LLC
1.40M
4.36%
+19.31K
+1.40%
Mar 31, 2025
State Street Global Advisors (US)
1.38M
4.28%
-62.15K
-4.32%
Mar 31, 2025
Invesco Advisers, Inc.
953.91K
2.97%
-27.98K
-2.85%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.77%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.07%
Invesco S&P SmallCap 600 Pure Growth ETF
0.9%
Lattice Hartford Multifactor Small Cap ETF
0.53%
Distillate Small/Mid Cash Flow ETF
0.49%
Harbor Human Capital Factor US Small Cap ETF
0.44%
Royce Quant Small-Cap Quality Value ETF
0.43%
Janus Henderson Small Cap Growth Alpha ETF
0.29%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.22%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.18%
Ver Mais
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.77%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporção1.07%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporção0.9%
Lattice Hartford Multifactor Small Cap ETF
Proporção0.53%
Distillate Small/Mid Cash Flow ETF
Proporção0.49%
Harbor Human Capital Factor US Small Cap ETF
Proporção0.44%
Royce Quant Small-Cap Quality Value ETF
Proporção0.43%
Janus Henderson Small Cap Growth Alpha ETF
Proporção0.29%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporção0.22%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proporção0.18%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
